MedicalCV AtriLaze
This article was originally published in The Gray Sheet
Executive Summary
Surgical cardiac tissue ablation system will begin U.S. shipping in January; the firm announced 510(k) clearance Dec. 13. MedicalCV plans a trial for an atrial fibrillation claim (1"The Gray Sheet" Nov. 29, 2004, p. 18)...
You may also be interested in...
Mechanical Valve Divestiture Is Defining Move For MedicalCV’s New CEO
MedicalCV will conduct an IDE clinical study to investigate its Atrilaze soft tissue ablation system for cardiac arrhythmias, following an initial 510(k) clearance
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.